Generic Drug Application Review Fairness Act of 2012
Latest action · Mar 30, 2012 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 29, 2012
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Generic Drug Application Review Fairness Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to extend from 30 to 60 months after application the period for a first applicant of a generic drug to obtain tentative approval without forfeiting the 180-day exclusivity period with respect to such drug, unless the failure in meeting the extended period is caused by a change in or review of approval requirements. Limits extension coverage to applications filed within 30 months preceding the enactment of this Act.
Reduces such extended period by six months per year over a five-year period, beginning on October 1, 2013.
Directs the Secretary of Health and Human Services (HHS) to maintain the Office of Generic Drugs as a separate office within the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA).
Cosponsors 6
Members who signed on, in the order they did. Signatures ran from Mar 29, 2012 to May 9, 2012; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-KY | Brett Guthrie | Original | Mar 29, 2012 |
| D-UT | Jim Matheson | Apr 18, 2012 | |
| R-TX | Michael C. Burgess | Apr 24, 2012 | |
| D-MI | John D. Dingell | Apr 25, 2012 | |
| D-CO | Diana DeGette | May 9, 2012 | |
| R-IL | Robert J. Dold | May 9, 2012 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 29, 2012 |
| Health Subcommittee | Referred Mar 30, 2012 |
Actions 3
Everything that happened, newest first.
- Mar 30, 2012Referred to the Subcommittee on Health.
- Mar 29, 2012Introduced in House
- Mar 29, 2012Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the page H1806.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 112-136 | FDA USER FEES 2012: HOW INNOVATION HELPS PATIENTS AND JOBS211 pages | Energy and Commerce Committee | Apr 18, 2012 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 5651 | Food and Drug Administration Reform Act of 2012 | Related bill | Jun 4, 2012 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act to extend the period for a first applicant, with respect to a generic drug, to obtain tentative approval without forfeiting the 180-day exclusivity period, and for other purposes.
- Short Titles as Introduced
- Generic Drug Application Review Fairness Act of 2012
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 29, 2012Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.